Clinical Trials
103 trialsCabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
RABBIT
University of Arizona
Cancer and Blood Pressure Management, CARISMA Study
Eastern Cooperative Oncology Group
Lumed
University Hospital, Basel, Switzerland
LIBRETTO-321
Eli Lilly and Company
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
LIBRETTO-001
Eli Lilly and Company
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Shanghai Jiao Tong University School of Medicine
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
LIBRETTO-531
Eli Lilly and Company
CAST-MTC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers
M.D. Anderson Cancer Center
LIBRETTO-121
Eli Lilly and Company
CMTpostopFDOPA
Institut Claudius Regaud
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Sanofi
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sanofi
EXAMINER
Exelixis
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
Peking Union Medical College Hospital
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
GFRα4 CAR T Cells in MTC Patients
University of Pennsylvania
MIMETIC
University Medical Center Groningen
ARROW
Hoffmann-La Roche
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
Instituto do Cancer do Estado de São Paulo
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
First Affiliated Hospital of Fujian Medical University
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
NantCell, Inc.
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
National Cancer Institute (NCI)
A Study of TY-1091 in Patients With Advanced Solid Tumors
TYK Medicines, Inc
AcceleRET-MTC
Hoffmann-La Roche
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
University College, London
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Boston Pharmaceuticals
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
Icahn School of Medicine at Mount Sinai
iTEP-CMT
Nantes University Hospital
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
University Hospital, Basel, Switzerland
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Columbia University
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
EXAM
Exelixis
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie